Plaintiffs Claim Manufacturers Did Not Provide Scientific Evidence to Justify Motion for Reconsideration





LOS ANGELES-Attorneys for the plaintiffs involved in a class action against the manufacturers of Paxil argue that GlaxoSmithKline's motion for reconsideration is not justified because it does not contain any new scientific evidence from the FDA that proves the drug is non-habit forming. In re: Paxil Litigation, No. 01-07937 (C.D. Calif.).

The Sept. 12 Response to the Brief of the United States of America and Opposition to GlaxoSmithKline's Motion for Reconsideration states that the FDA's letter of interest focused on federal preemption and primary jurisdiction issues rather than in-depth analysis of whether the Paxil advertisements are misleading to …






UPCOMING CONFERENCES




HarrisMartin's Webinar Series: Video Game Addiction Product Liability Litigation

March 29, 2024

MORE DETAILS



HarrisMartin's Masters of Mass Tort Settlements Conference - Sponsored by Milestone

June 27, 2024 - Buffalo, NY
The Richardson Hotel Buffalo

MORE DETAILS